Positive impactOrders & Deals
Sun Pharma, Cipla have more upside; Chinese drug deals may lower oncology costs: Systematix
CNBC-TV18 1 hr ago·1 Sept 2026, 10:43 am
Systematix analysts see significant growth potential for Indian pharmaceutical companies, particularly Sun Pharma and Cipla. They believe these large players are well-positioned to benefit from the ongoing trend of Indian firms partnering with Chinese manufacturers to boost scale and production volumes. This strategic collaboration is expected to drive efficiency and help manage costs.
For investors, this signals a positive outlook for the sector. The focus on volume and cost control could make Indian drugs more competitive globally. Additionally, analysts highlight that smaller Contract Development and Manufacturing Organizations (CDMOs) might offer stronger upside as they secure new contracts and capture emerging opportunities in the supply chain.
Investors should monitor the progress of these partnerships and the resulting impact on oncology drug pricing. Keeping an eye on new contract awards for CDMOs will also be key to understanding the sector's growth trajectory.
Excerpt from CNBC-TV18
Vishal Manchanda, Pharma Analyst at Systematix Group, expects more Indian drugmakers to partner with Chinese pharma companies, with their focus on scale and volumes potentially bringing down oncology drug prices. Manchanda also sees smaller CDMO companies offering stronger upside as new contracts and opportunities…Read the original at CNBC-TV18
Key takeaways
- Category: Orders & Deals.
- AI reads the tone as positive (potentially bullish) for the stock.
- Assessed as a significant, market-relevant update.
Why it matters
A meaningful update worth tracking. The tone is positive — historically associated with upward pressure, though not predictive. Use the price and stock snapshot to gauge how the market is responding.
